Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEA-targeted CAR-T cells · 4 trials · 12 indications
Incidence of adverse events during the study, evaluated per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) criteria
Dose-limiting toxicity after CEA CAR-T cell infusion
The incidence of adverse events after CEA CAR-T cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)
The incidence of adverse events (TEAE) after treatment; Incidence of treatment-related adverse events; Adverse evens of Special Interest (AESI);
Incidence and number of dose-limiting toxicity (DLT) cases，Dose-limiting toxicity after CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-15x10\^5 cells/kg |
| Intrapleural infusion of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-15x10\^5 cells/kg |
| Intraperitoneal infusion of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-15x10\^5 cells/kg |
| intraperitoneal injection of CEA-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| Intravenous of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| intraperitoneal injection of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CEA-targeted CAR-T cells by dose of 1-10x10\^6 cells/kg |
| Name | Type | Description |
|---|---|---|
| CEA-targeted CAR-T cells | BIOLOGICAL | Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion. |
Inclusion Criteria: 1. Age ≥ 18 years, no gender restriction; 2. Histopathologically confirmed diagnosis of advanced, metastatic, or recurrent malignant tumors, primarily including colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, lung cancer, and cholangiocarcinoma; 3. Failu...
Top 20 of 76 competitors
CEA-targeted CAR-T cells is an investigational cell therapy being studied for CEA-positive advanced solid tumors, including lung cancer, colorectal cancer, and gastric cancer. It is in Phase 1 clinical development for these indications.
CEA-targeted CAR-T cells targets carcinoembryonic antigen (CEA), a protein expressed on the surface of certain tumor cells. The therapy is designed to recognize and attack CEA-positive cancer cells in patients with advanced solid tumors.
CEA-targeted CAR-T cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker DTIL. The therapy is currently in Phase 1 clinical trials.
CEA-targeted CAR-T cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. Multiple Phase 1 trials are currently recruiting patients with CEA-positive advanced solid tumors.
CEA-targeted CAR-T cells is being studied in several Phase 1 trials, including NCT06006390, NCT06043466, NCT06126406, and NCT07179692. These trials are recruiting patients with various CEA-positive advanced solid tumors, such as gastric, colorectal, and lung cancers.
CEA-targeted CAR-T cells is a specific chimeric antigen receptor T-cell therapy that targets CEA. It is distinct from CAR-T therapies targeting other antigens, such as CD19 or BCMA, which are used for different cancer types.